EGFR and cancer: Erlotinib inhibits the growth of cancer cells and displays anticancer activity by selectively inhibiting tyrosine kinase autophosphorylation of the EGFR of cancer cells and suppressing the activity of its downstream Ras/MAPK signaling pathway [24].